Seòmar agus comataidhean

Thanks to the progress we have made with widespread vaccination and new Covid treatments, which have reduced the severe health harms of the virus, the purpose of testing has changed from population-wide testing to reduce transmission to targeted testing to support clinical care. As a result, most people in Scotland no longer need to test for Covid.

Some people do remain at higher risk – primarily people who are immunosuppressed. These people should continue to follow the advice of their GP or specialist clinician, who best know their health condition and individual circumstances. Those that have a health condition which means they’re eligible for Covid treatments can continue to access testing.

Following a meeting with the Isle of Rum Community Trust on Wednesday 2 nd November, I agreed that more time is necessary to work with the community to try and secure a positive future for the Castle, that can be supported by the community on the Isle of Rum. Any changes to the vehicle servitude rights in front of the castle would in any case require the agreement of the Isle of Rum Community Trust.

Work is currently underway to develop an updated Sexual Health and Blood Borne Viruses Framework.

The Scottish Government has set up a steering group to bring together key stakeholders from across the sector to ensure that the new Framework is fit for purpose and supports ambitions to preserve Scotland's capability to deliver world-leading sexual health services, whilst also identifying key priorities which will require dedicated focus over the coming years.

The steering group, which includes representatives from NHS Boards, Public Health Scotland and third sector organisations, has been consulted on the content and format of the updated Framework, and they will continue to be called upon to comment on the document at all stages of development.

Broader consultation will also be undertaken during the drafting process, to ensure a wide range of stakeholder views can be heard.

No data is collected on the return or disposal of medicines due to the difficult nature of quantifying and recording this information. Health Boards are responsible for ensuring unused medicines are safely disposed of, though are not required to record this data.

The Scottish Government continues to closely monitor the outcomes of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence. The RAPID C-19 group is a collaborative UK-wide partnership between the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and others. To date, the RAPID C-19 group and the COVID-19 UK expert panel have both considered a full range of evidence, including clinical trial data, in vitro (in the laboratory) analysis and observational studies and have advised that there is insufficient evidence available at this time to support the procurement and deployment of Evusheld ® .

The RAPID C-19 group is keeping this position under active review, including through monitoring any emerging data. Building on the work of the RAPID C-19 group, the SMC is exploring the potential for collaboration with NICE on a single technology assessment (STA) of tixagevimab–cilgavimab (Evusheld ® ) for the prevention of COVID-19. In order to gain further evidence, consideration is also being given to establishing a clinical trial as a route to answering outstanding questions on the link between in vitro tests and clinical outcomes for current and future variants, which is currently not known. The trial may also assist with evaluating the effectiveness and safety of a higher dose of 600mg, which is now being used in a number of countries, which have previously purchased Evusheld®, as this was not tested in the company’s randomised controlled trials.

I have recently written to the UK Government supporting the establishment of a clinical trial and stating my wish to see individuals in Scotland included.

The information requested is not held centrally.

We expect all NHS Boards to have robust governance arrangements in place, including those for risk assessment and business continuity; as informed by, and consistent with, national policies and frameworks. NHS Lanarkshire has confirmed that, as part of their routine winter planning work, they have been engaging with local planning partners to ensure all eventualities are carefully considered.

An estimate of the number of people with complex disabilities was published by the charity Sense in a short report in May 2022, which estimated that there were around 157,000 people in Scotland that could have complex disabilities, where complex disabilities were defined as a person having two or more of the following conditions: ‘deaf or hearing impairment’, ‘blind or vision impairment’, ‘learning disability’, ‘autism’. A link to the report is available here: https://www.sense.org.uk/about-us/statistics/complex-disabilities-in-scotland/

The decision not to procure Evusheld ® at this time has been taken based on clinical advice, rather cost.

The RAPID C-19 group is a collaborative UK-wide partnership between the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and others. To date, the RAPID C-19 group and the COVID-19 UK expert panel have both considered a full range of evidence, including clinical trial data, in vitro (in the laboratory) analysis and observational studies and have advised that there is insufficient evidence available at this time to support the procurement and deployment of Evusheld ® .

The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.

I refer the member to the answer to question S6W-11806 on 15 November 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .